ALADDIN (Accelerated Discovery Nanobody Platform) is a research project funded by the European Innovation Council (EIC). The goal of the project is to develop and bring to the market a platform that improves the generation and identification of therapeutic nanobodies and their preclinical validation for human cancer.
 
The four-year project, which started in January 2024, will organise its first in-person meeting between the consortium’s partners this October 16–17 in Madrid, Spain. The meeting is hosted by the project’s coordinating institution, the Spanish Centro Nacional de Biotecnología (CNB-CSIC).
 
We’ll update the key insights of the meeting here on the ALADDIN website. Stay tuned to our social media accounts on LinkedIn and X for more updates!